Navigation Links
Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released
Date:10/10/2007

LYON, France & NORTH BRUNSWICK, N.J.--(October 10, 2007)--World Vaccine Congress: A first-in-man trial of a live Listeria vaccine was reported by Advaxis Inc. (OTCBB: ADXS - News). The Phase I/II trial was testing Lovaxin C in advanced cervical cancer patients. Lovaxin C is being developed by Advaxis as an immunotherapy that is intended to treat patients with cancers that result from human papilloma virus (HPV), including cervical cancer and head and neck cancer.

In the safety study, Advaxis reported treating fifteen patients in three dosage groups with thirty-minute 250 ml infusions of Lovaxin C at three-week intervals. Patients were observed for a total of 111 days. All patients had either advanced, recurrent, or progressive cervical cancer, and with the exception of two women, all patients were stage IVb (end stage). Every patient experienced a flu-like syndrome in the three-to-twelve hours after dosing comprised of fever, chills, nausea, and occasional vomiting, which is consistent with immune stimulation. In the lower two doses, symptoms were well tolerated and resolved with the use of over the counter analgesics and antihistamines. In the highest cohort the pattern of symptoms was the same, however more severe and dose limiting; which required that the study be stopped at that point as a dosage ceiling was defined. The endpoint of the study, safety, was met as the assessments confirmed that Lovaxin C was safe to administer intravenously, that the pattern of adverse responses observed, as previously stated above, were consistent with immune stimulation, and that, for this population of patients, a dosage ceiling was determined.

Although efficacy was not a primary endpoint anecdotal information was obtained. Patients' tumors were assessed by CT scans and any tumor changes were scored using RECIST criteria. Two patients had only a single tumor measurement, making the assessable efficacy population thirteen patients. It was observed that fiv
'/>"/>

Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Advaxis, Inc.
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. SARS-Free Taiwan to Mark End Phase of Global Fight
3. S. Africa AIDS in death phase
4. Spray on contraceptive clears Phase I trial
5. Phase 3 trials of two multi-kinase inhibitors against cancer
6. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
7. Phase II trails of new HIV vaccine to be held in South Africa
8. Phase 1 Drug Trials on Humans to Be Made Public
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
11. Cadila to Commence Phase I Clinical Trials On ZYH2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)...e based in the Northeast region with more hires,pl...HARRISBURG, Pa., Aug. 28 /PRNewswire-USNewswire/ -...red a Patient Safety Liaison for the,Northeast reg...he,Pennsylvania Patient Safety Reporting System (P...tizens., "Last year in focus groups with Pennsylv...
(Date:8/28/2008)... Leading dermatology company serves growing pro... Palo Alto, CA (PRWEB) August 28,... capital firm, today announced that together with ... is leading a Series A round of financing for Prof...ntly invested $15.5 million in the round. Profex, ...
(Date:8/28/2008)...jury, not injury itself, associated with increased... News) -- A group of researchers has described hou...ght to play a key role in Alzheimer,s disease. ,...beta, was directly linked to brain cell communicat...brain cell communication increased, so did amyloid...
(Date:8/28/2008)... The Accreditation Council for Continuing Medic...ision of the College of American Pathologists (CAP... a provider of continuing medical education for ph...L (PRWEB) August 28, 2008 -- The Accreditation Cou...awarded the Education Division of the www.cap.org...
Breaking Medicine News(10 mins):Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2Health News:College of American Pathologists' Education Division Receives Top Honor 2Health News:College of American Pathologists' Education Division Receives Top Honor 3
...ty Medical Center reveal a surprising new origin f...apparatus -- a stack of pancake-shaped compartmen...ular destinations -- is the source of a particular... Scientists have long thought that microtubules, ...
...ancer treatment comes in the form of Intraoperativ... of radiation during surgery . Thus the patient ca...the Princess Margaret Hospital team combined the e...cine specialists (radiation oncologists, physicist...
... Wednesday toward offering vaccinations against ce... that could be carried out by late next year. The...JCVI) recommended the use of vaccines to guard aga... transmitted infection which causes most cases of ...
...ersity School of Medicine in St. Louis have just g...ealing that smoking interferes with ligament heal...model and found that cigarette smoking impairs the...ite and delays healing following ligament repair s...
Other Medicine News:Health News:Research in the Origin of Microtubules 2Health News:Research in the Origin of Microtubules 3Health News:Intraoperative Radiation Therapy a New Step in Breast Cancer Treatment 2Health News:Girls Could Be Vaccinated Against Cervical Cancer in Britain 2Health News:Smoking Hampers Healing of the Ligament 2
(Date:8/28/2008)...rents to protect their 11- and 12-year-olds from,m...es cervical cancer, ATLANTA, Aug 28 /PRNewswire-U...Prevention,s (CDC) National Center for Immunizatio...w public service announcements,(PSAs) targeting th...ast,organizations. The television and radio spots,...
(Date:8/28/2008)...swire-FirstCall/ --, - Results Further Support th... Under Development to Improve the Survival of Pati...), Algeta ASA (OSE: ALGETA), the Norwegian cancer...imary objective of its BC1-03 Phase II pain,pallia...gle doses of,Alpharadin in patients with painful b...
(Date:8/27/2008)...m Makes Crucial Breakthrough in Battle to Prevent ... CHICAGO, Aug. 27 /- The British Mid... scientists at The University of Nottingham,have m...r prevent the onset,of a very common type of demen...e genetically produced the first ever mouse model,...
(Date:8/26/2008)...- The Oregon Tourism Commission,launc...ice Training Program,(Q Care) this week on http:/...ng program created to support the tourism and,hosp...on. By emphasizing,the importance of quality custo...h tools and resources to better serve Oregon,s vis...
Breaking Medicine Technology:Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Long Term Care Insurance Leader Offers Advice on Preventing Dementia the Leading Cause of Care Claims 9944 1Long Term Care Insurance Leader Offers Advice on Preventing Dementia the Leading Cause of Care Claims 9944 2Divine Corporations Personal Lubricants Shown to Block Cancer causing Viruses in a Study by the National Cancer Institute 1246 1Divine Corporations Personal Lubricants Shown to Block Cancer causing Viruses in a Study by the National Cancer Institute 1246 2LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 1LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 2Ohio Prematurity Caucus Forming to Meet Challenge 9938 1Ohio Prematurity Caucus Forming to Meet Challenge 9938 2Ohio Prematurity Caucus Forming to Meet Challenge 9938 3
..., 2007 /PRNewswire/ -- Asenapine -- an,investigati...althcare business unit of Akzo Nobel, for bipolar ...o be more effective than placebo,in treating acute...I disorder, according to new Phase III results, fr...ssociation,s 2007 Annual,Meeting. , In the three-w...
...t 2007 APA Meeting -, COLLEGEVILLE, Pa., May 21, 2...tudies examining safety and efficacy of,desvenlafa...e,inhibitor (SNRI) being studied as a potential tr...(MDD), were presented today at the,2007 American P...,Calif., by Wyeth Pharmaceuticals, a division of ...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: